文献速递免疫规划传染病防控与疫情报告

卡介苗接种对结核病患者结局影响的观察性研究

Exploring the effects of BCG vaccination in patients diagnosed with tuberculosis: Observational study using the Enhanced Tuberculosis Surveillance system.
PubMed 文献 · Vaccine · 2019-07-08

基于英格兰2009-2015年增强结核病监测系统的所有结核病通知数据,采用逻辑回归分析卡介苗接种与全因死亡、结核死亡、复发、肺部疾病及痰涂片状态的关系。发现卡介苗接种与全因死亡降低相关(aOR 0.76,95%CI 0.64-0.89,P=0.001),与复发结核关联证据较弱(aOR 0.90,95%CI 0.81-1.00,P=0.056);多重插补分析提示接种超过10年后全因死亡获益减弱。

要点

  • 卡介苗接种与结核病患者全因死亡降低相关,aOR 0.76(95%CI 0.64-0.89)。
  • 与复发结核关联证据较弱,aOR 0.90(95%CI 0.81-1.00,P=0.056)。
  • 多重插补分析提示接种超过10年后全因死亡获益减弱。

核心结论

  • 卡介苗接种与结核病患者全因死亡降低相关,但接种超过10年后获益减弱。
  • 卡介苗接种与复发结核的关联证据较弱。

研究设计与样本

  • 观察性研究,使用英格兰2009-2015年增强结核病监测系统的所有结核病通知数据。
  • 采用逻辑回归进行完整病例分析,调整潜在混杂因素,并用多重插补数据重复分析。

主要发现

  • 卡介苗接种与全因死亡降低相关,aOR 0.76(95%CI 0.64-0.89),P=0.001。
  • 卡介苗接种与复发结核关联较弱,aOR 0.90(95%CI 0.81-1.00),P=0.056。
  • 多重插补分析提示接种超过10年后全因死亡获益减弱。

关键数值与推荐

  • 全因死亡:aOR 0.76(95%CI 0.64-0.89),P=0.001。
  • 复发结核:aOR 0.90(95%CI 0.81-1.00),P=0.056。

临床怎么用

  • 提示卡介苗接种可能对结核病患者全因死亡有额外获益,但需考虑接种后时间。
  • 应结合监测数据评估卡介苗接种对结核病结局的长期影响。

局限性

  • 观察性设计,可能存在残余混杂。
  • 完整病例分析可能引入选择偏倚,虽用多重插补验证。
  • 监测数据中卡介苗接种信息可能不完整或存在错分。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bacillus Calmette-Guérin (BCG) is one of the most widely-used vaccines worldwide. BCG primarily reduces the progression from infection to disease, however there is evidence that BCG may provide additional benefits. We aimed to investigate whether there is evidence in routinely-collected surveillance data that BCG vaccination impacts outcomes for tuberculosis (TB) cases in England. METHODS: We obtained all TB notifications for 2009-2015 in England from the Enhanced Tuberculosis surveillance system. We considered five outcomes: All-cause mortality, death due to TB (in those who died), recurrent TB, pulmonary disease, and sputum smear status. We used logistic regression, with complete case analysis, to investigate each outcome with BCG vaccination, years since vaccination and age at vaccination, adjusting for potential confounders. All analyses were repeated using multiply imputed data. RESULTS: We found evidence of an association between BCG vaccination and reduced all-cause mortality (aOR:0.76 (95%CI 0.64-0.89), P:0.001) and weak evidence of an association with reduced recurrent TB (aOR:0.90 (95%CI 0.81-1.00), P:0.056). Analyses using multiple imputation suggested that the benefits of vaccination for all-cause mortality were reduced after 10 years. CONCLUSIONS: We found that BCG vaccination was associated with reduced all-cause mortality in people with TB although this benefit was less pronounced more than 10 years after vaccination. There was weak evidence of an association with reduced recurrent TB.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Abbott S, Christensen H, Lalor MK, et al. Exploring the effects of BCG vaccination in patients diagnosed with tuberculosis: Observational study using the Enhanced Tuberculosis Surveillance system. Vaccine. 2019. PMID: 31296375. doi:10.1016/j.vaccine.2019.06.056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。